- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Education, Provider Education, and Overall Final Thoughts
In this discussion, panelists offer their final thoughts.
EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria
EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria
EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria
EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria
EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria
EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment
EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
EP: 13.Patient Education, Provider Education, and Overall Final Thoughts
Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients
September 25th 2024A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Read More
Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color
September 17th 2024Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Read More
Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials
September 17th 2024Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
Read More
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
September 16th 2024The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Read More
